acebutolol has been researched along with procainamide in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 6 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giacomini, KM; Schaner, ME; Zhang, L | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anderson, JL; Harrison, DC; Meffin, PJ; Winkle, RA | 1 |
| Stevens, MB | 1 |
| Hein, DW; Weber, WW | 1 |
| Dreifus, LS; Morganroth, J | 1 |
| Ayer, LM; Dixon, GH; Fritzler, MJ; Rubin, RL | 1 |
| Das Gupta, V | 1 |
| Alexander, KS; Parker, GA; Pudipeddi, M | 1 |
3 review(s) available for acebutolol and procainamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
N-acetylation pharmacogenetics.
Topics: Acebutolol; Acetyl Coenzyme A; Acetylation; Acetyltransferases; Aminoglutethimide; Animals; Anti-Anxiety Agents; Benzodiazepines; Caffeine; Carcinogens; Cricetinae; Dapsone; Disease; Drug-Related Side Effects and Adverse Reactions; Ethnicity; Genotype; Humans; Hydrazines; Kinetics; Liver; Mice; Models, Biological; Mutagens; Pharmaceutical Preparations; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Procainamide; Rabbits; Species Specificity; Substrate Specificity; Sulfasalazine | 1985 |
Antiarrhythmic agents and their use in therapy.
Topics: Acebutolol; Animals; Anti-Arrhythmia Agents; Digitalis Glycosides; Disopyramide; Humans; Lidocaine; Oxytocin; Phenytoin; Procainamide; Propranolol; Quinidine; Verapamil | 1980 |
21 other study(ies) available for acebutolol and procainamide
| Article | Year |
|---|---|
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Topics: Carrier Proteins; Corticosterone; HeLa Cells; Humans; Membrane Proteins; Midazolam; Organic Cation Transporter 1; Permeability; Recombinant Proteins; Structure-Activity Relationship; Tetraethylammonium Compounds; Transfection | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.
Topics: Acebutolol; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Bretylium Compounds; Digitalis Glycosides; Disopyramide; Humans; Kinetics; Lidocaine; Mexiletine; Oxytocin; Phenytoin; Procainamide; Propranolol; Quinidine; Verapamil | 1978 |
Drug-induced lupus.
Topics: Acebutolol; Adult; Aged; Antibodies, Antinuclear; Blood Sedimentation; Female; Humans; Lupus Erythematosus, Systemic; Procainamide | 1992 |
Antibodies to HMG proteins in patients with drug-induced autoimmunity.
Topics: Acebutolol; Autoantibodies; Autoimmune Diseases; Autoimmunity; Enzyme-Linked Immunosorbent Assay; High Mobility Group Proteins; Humans; Immunoblotting; Lupus Vulgaris; Procainamide; Sulfasalazine | 1994 |
Complexation of procainamide with hydroxide-containing compounds.
Topics: Chemical Phenomena; Chemistry, Physical; Ethanol; Fructose; Glucose; Glycerol; Hydroxides; Lactose; Maltose; Procainamide; Propylene Glycols; Sorbitol; Sucrose | 1983 |
Stability of procainamide hydrochloride syrups compounded from capsules.
Topics: Capsules; Chromatography, High Pressure Liquid; Drug Compounding; Drug Stability; Maltose; Procainamide; Solutions; Sucrose; Sugar Alcohols | 1993 |